[IBB] iShares Nasdaq Biotechnology Index Fund

Overview

Type of security: Fund

Tags: Biotech, Country, Equity, ETF, Health, Health care, Healthcare, Index Based, Not Inversed, Sector, Stocks, U.S., Unleveraged

The data is delayed by 15 minutes.

 

Price: 272.32 Change: 5.62 (2.11%)
Ext. hours: 274.4 Change: 2.08 (0.76%)

chart IBB

Refresh chart

Strongest Trends Summary For IBB

IBB is in the medium-term down -9% below S&P in 4 months. In the long-term up 42% above S&P in 20 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Technical Data
High 52 week122.16 Low 52 week89.61 Last close103.77 Last change-0.64%
RSI39.15 Average true range2.42 Beta0.99 Volume1.25 M
Simple moving average 20 days-1.64% Simple moving average 50 days-4.82% Simple moving average 200 days-5.74%
Performance Data
Performance Week-1.17% Performance Month-1.3% Performance Quart-7.38% Performance Half-0.25%
Performance Year-3.36% Performance Year-to-date7.61% Volatility daily1.35% Volatility weekly3.01%
Volatility monthly6.17% Volatility yearly21.36% Relative Volume180.65% Average Volume2.72 M
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings0
Price to Book Value 9.9 Price to Earnings40.91 Total expense ratio0.48% Total net assets4.92 B
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Total Expense Ratio0,48
Number Of Holdingsn/a
Total Net Assets4 915 409 116,00
P/E Ratio40,91
P/Bv Ratio9,9
Top Holdings:
NAME VALUE
Amgen Inc8,91
Biogen Idec Inc8,04
Celgene Corp7,78
Gilead Sciences Inc7,67
Alexion Pharmaceuticals Inc6,78
Regeneron Pharmaceuticals Inc4,04
Mylan Inc3,93
Vertex Pharmaceuticals Inc3,92
Illumina Inc3,88
Biomarin Pharmaceutical Inc2,36
Sector Breakdown:
NAME VALUE
Biotechnology78,14
Pharmaceuticals21,85
S-t Securities0,04

News

2019-06-21 09:15:01 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-06-21 07:31:00 | ContraVir's stock rockets off record low after 'positive feedback' on pre-IND for NASH

2019-06-17 13:31:00 | Adaptive Biotechnologies sets terms for IPO, to raise up to $212.5 million

2019-06-17 13:17:00 | Karuna Therapeutics sets IPO terms, to be valued at up to $363 million

2019-06-14 09:50:00 | Morphic Holding sets terms of IPO to raise up to $80 million

2019-06-14 07:48:00 | Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal

2019-06-13 07:27:00 | Provention Bio's stock surges after calling off public stock offering

2019-06-12 06:29:46 | Barclays Has New Plays for Healthcare Fans

2019-06-07 08:56:00 | Cancer genomics company Personalis expects to raise up to $107 million in IPO

2019-06-04 11:07:35 | Biotech Sector Could Enter Bear Market

2019-05-30 06:53:10 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-05-23 13:21:00 | Ideaya Biosciences' stock opened 40% above its IPO price, then pared most of its gains

2019-05-20 09:02:00 | Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days

2019-05-17 09:47:00 | Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days

2019-05-15 06:55:16 | Foamix FOMX: A Beaten-Down Biotech Stock That Looks Like a Bargain Now

2019-05-13 22:54:31 | Reaping the Benefits of In-Depth Knowledge of ETFs

2019-05-13 14:15:06 | FDA Issues Final Guidelines To Make Interchangeable Biosimilars More Easily Available

2019-05-09 07:46:00 | These 3 revolutionary genomics companies are changing lives for patients — and investors

2019-05-07 16:57:08 | Biotech ETFs in Focus on String of Q1 Earnings Beats

2019-05-02 13:21:00 | These 6 biotech stocks are promising takeover targets

2019-04-30 13:00:34 | Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

2019-04-30 10:39:00 | Axcella Health sets IPO terms, which could value the biotech at up to $505.7 million

2019-04-26 14:01:00 | Gilead Stock Is Due for a Comeback, Analyst Says

2019-04-25 13:26:09 | Can Health Care Recover from Medicare for All?

2019-04-24 16:04:08 | Will Biotech ETFs Continue to Rally in Q1 Earnings?

2019-04-18 12:17:58 | Intuitive Surgical Stock Is Down but Not Out

2019-04-18 07:00:00 | Mustang Bio's stock soars to near 4-fold gain after deal to commercialize 'bubble boy' disease treatment

2019-04-15 13:49:47 | ImmunoGen Stock Is in Trouble Going Into Earnings

2019-04-15 10:46:00 | Bio-Path's stock rockets after withdrawal of stock offering

2019-04-12 08:16:00 | Biotech company Axcella Health files for IPO

2019-04-12 07:23:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-04-10 16:44:08 | Global X Launches GNOM ETF to Tap Booming Genomics Space

2019-04-10 11:11:10 | Is AstraZeneca Stock Worth Buying Before Earnings?

2019-04-08 15:09:00 | Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling

2019-04-03 12:23:00 | Democrats, Republicans agree on legislation targeting drug prices

2019-04-03 07:44:00 | Advaxis' stock plummets after public offering prices at deep discount

2019-04-02 09:00:00 | ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment

2019-03-26 07:51:00 | Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints

2019-03-25 09:26:00 | Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties

2019-03-25 08:49:00 | 5 biotech stocks that could be the next big winners

2019-03-25 07:26:00 | Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge

2019-03-21 11:16:40 | Biotech Funds Could Generate Profitable Short Sales

2019-03-21 09:46:59 | Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial

2019-03-21 06:52:00 | Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role

2019-03-20 07:07:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-03-18 15:05:00 | Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment

2019-03-18 13:12:00 | Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study

2019-03-18 07:29:00 | PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent

2019-03-14 15:51:00 | Gilead Stock Could Surge to $84, Says Analyst

2019-03-13 10:35:00 | Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting